medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2006; 5 (2)


Beta blockers in portal hypertension. Are they really a good option?

López-Méndez E, Uribe M

Idioma: Ingles.
Referencias bibliográficas: 42
Paginas: 86-91
Archivo PDF: 89.65 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bathal PS, Groszmann RJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985; 1: 325-29.

  2. Groszmann RJ, Bosch J, Grace ND, Conn HO, García-Tsao G, Navasa M, Alberts J, et al. Hemodynamics events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990; 99: 1401-07.

  3. Bosch J, García-Pagán JC. Complications of cirrhosis. Portal hypertension. J Hepatol 2000; 32: 141-56.

  4. D´Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332-54.

  5. De Franchis R. Updating consensus in portal hypertension : Report of the Baveno III Consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 2000; 33: 846-52.

  6. D´Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999; 19: 475-505.

  7. Armonis A, Patch D, Burroughs A. Hepatic venous pressure measurement: and old test as a new prognostic marker in cirrhosis? Hepatology 1997; 25: 245-48.

  8. Feu F, García-Pagán JV, Bosch J, Luca A, Teres J, Escorcell A, Rodes J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346: 1056-59.

  9. Abraldes J, Tarantino I, Turnes J, García-Pagán JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37: 902-08.

  10. Villanueva C, López-Balaguer J, Aracil C, Kolle L, Gonzalez B, Miñana J, Soriano G, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. Journal of Hepatology 2004; 40: 757-65.

  11. García-Pagán JC, Feu F, Bosch J, Rodes J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 1991; 114: 869-73.

  12. Merkel C, Sacerdoti C, Bolognesi M, Enzo E, Marin R, Bombonato G, Angeli P, et al. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone. Hepatology 1997; 26: 34-39.

  13. Merkel C, Marin R, Sacerdoti C, Donada C, Cavallarin G, Torboli P, Amodio P, et al. Long term results of a clinical trail of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 31: 324-29.

  14. García-Pagán J, Morillas R, Bañares R, Albillos A, Villanueva C, Vila C, Genesca J, et al. Propranolol plus placebo vs propranolol plus isosorbide-5-mononitrate in the prevention of the first variceal bleed. A double blind RCT. Hepatology 2003; 37: 1260- 66.

  15. García-Pagán J, Escorcell A, Moitinho E, Bosch J. Influence of pharmacological agents on portal hemodynamics: Basis for it use in the treatment of portal hypertension. Semin Liver Dis 1999; 19: 427-38.

  16. Imperiale TF, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 2001; 33: 802-7.

  17. De Franchis R. Evolving consensus in portal hypertension : Report of the Baveno IV Consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005; 43: 167-76.

  18. Lo GH, Chen WC, Chen MH, Lin CP, Lo CC, Hsu P, Cheng JS, et al. Endoscopic ligation vs Nadolol in the prevention of first variceal bleeding in patients with cirrhosis. Gastrointestinal Endoscopy 2004; 59: 333-8.

  19. Agarwal SR, Singh J, Sharma BC, Sarin SK. Combination of endoscopic variceal ligation and propranolol with endoscopic variceal ligation alone in the prevention of first variceal bleed: an interm analysis. Journal of Hepatology 2002; 36: 196A.

  20. Sarin SK, Wadhawan M, Agarwal SR, Tyagy P, Sharma BC. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding. Am J Gastroenterol 2005; 100(4): 797-804.

  21. Gournay J, Masliah C, Martin T, Perrin D, Galmiche JP. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000; 31: 1239-45.

  22. Bureau C, Peron JM, Alric L, Morales J, Sanchez J, Barange K, Payen JL, et al. «A la carte» treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002; 36: 1361-66.

  23. Lo GH, Lai KH, Cheng JS, Chen MH, Huang HC, Hsu P, Lin CK. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology 2000; 32: 461-65.

  24. De la Peña J, Brullet E, Sanchez-Hernández E, Rivero M, Vergara M, Martin-Lorente JL, Garcia-Suárez C, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: A multicenter trial. Hepatology 2005; 41: 572-78.

  25. Villanueva C, Miñana J, Ortiz J, Gallego A, Soriano G, Torras X, Sainz S, el al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345: 647-55.

  26. Patch D, Sabin CA, Goulis J, Gerunda G, Merkel C, Greenslade L, Burroughs AK. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002; 123: 1013-19.

  27. Lo GH, Chen WC, Chen MH, Hsu PI, Lin CK, Tsai WL, Lai KH. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology 2002; 123: 728-34.

  28. Bosch J, García-Pagán JC. Prevention of variceal rebleeding. Lancet 2003; 361: 952-54.

  29. De Franchis R, Primignani M. Endoscopic treatments for portal hypertension. Semin Liver Dis 1999; 19: 439-55.

  30. Escorcell A, Banares R, García-Pagán JC, Gilabert R, Moitinho E, Piqueras B, Bosch J, et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trail. Hepatology 2002; 35: 385-92.

  31. Bureau C, García-Pagán JC, Otal P, Pomier G, Chabbert V, Cortez C, Perreault P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: Results of a randomized study. Gastroenterology 2004; 126: 469-75.

  32. Bosch J, Abraldes J, Groszmann R. Current management of portal hypertension. Journal of Hepatology 2003; 38: S54-68.

  33. Abraczinkas DR, Ookubo R, Grace ND, Groszmann RJ, Bosch J, García-Tsao, Rodés J, et al. Propranolol for the prevention of first esophageal variceal hemorrage: a lifetime commitment? Hepatology 2001; 34: 1096-1102.

  34. Bañares R, Moitinho E, Piqueras B, Casado M, García-Pagán JC, Diego A, Bosch J. Carvedilol, a new non selective beta-blocker with intrinsic anti-alpha 1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology 1999; 30: 79-83.

  35. Bañares R, Moitinho E, Matilla A, García-Pagán JC, Lampreave JL, Piera C, G-Abraldes L, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002; 36: 1367-73.

  36. Lin HC, Soubrane O, Cailmail S, Lebrec D. Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats. J Hepatol 1991; 13: 213-219.

  37. García-Pagán JC, Fernández M, Pizcueta MP, Bosch J, Rodes J. Continued propranolol administration attenuates the hemodynamic disturbances associated with the development of portal hypertension in rats with secondary biliary cirrhosis. Biennial Scientific Meeting of AISL, Brighton 1992, Abstract OP 72.

  38. Calés P, Oberti F, Payen JL, Naveau S, Guyader D, Blanc P, Abergel A, et al. Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French speaking club for the study of portal hypertension. Eur J Gastroenterol Hepatol 1999; 11: 741-5.

  39. Merkel C, Marin R, Angelini P, Zanella P, Felder M, Bernardinello E, Cavallarin G, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004; 127: 476-84.

  40. Ryan B, Stockbrugger R, Ryan M. A pathophysiologic, gastroenterologic and radiologic aproach to the management of gastric varices. Gastroenterology 2004; 126: 1175-1189.

  41. Escorcell A, Bordas JM, Castañeda B, Llach J, García-Pagán JC, Rodés J, Bosch J. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 2000; 31: 1061- 67.

  42. Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Torras X, Cusso X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334(25): 1624-29.




2020     |     www.medigraphic.com